Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Rituximab in R/R DLBCL
NCT04425824Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in diffuse large B-cell lymphoma (DLBCL), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
toripalimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04425824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425824.